Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Genes - 10 Feb 2026

Duminuco Andrea, Vitale Silvia Rita, Nardo Antonella, Harrington Patrick, Stella Stefania, Massimino Michele, Tomarchio Cristina, Mauro Elisa, Parisi Marina S, Maugeri Cinzia, Di Raimondo Francesco, Palumbo Giuseppe A, Manzella Livia, Vetro Calogero

Abstract excerpt

Background: Acute myeloid leukemia (AML) is genomically heterogeneous, and translating baseline molecular data into individualized prognosis remains difficult. We assessed real-world outcomes and externally validated the Sanger Institute AML multistage prognostic model. Methods: This single-center, retrospective study included 73 AML patients who underwent targeted NGS profiling. In intensively treated patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41751601
DOI: 10.3390/genes17020218
PMCID: PMC12941301

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.PMID 41751601Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Genomic and clinical determinants of outcome in Irish AML: a real-world analysis (2007-2025), single centre experience.Semantic proximity Read ↗

Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.Semantic proximity Read ↗

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.Semantic proximity Read ↗

Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomesSemantic proximity Read ↗

Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemiaSemantic proximity Read ↗

Precision survival estimation in acute myeloid leukemia using evolutionary learning-derived microRNA signatureSemantic proximity Read ↗

Multiparameter prediction of myeloid neoplasia risk.Semantic proximity Read ↗

Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignanciesSemantic proximity Read ↗

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportSemantic proximity Read ↗

Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.